MPZL3 and glioblastoma: Concerning prognosis, patients with high MPZL3 expression had a relatively worse OS in ACC, BRCA, GBM, LAML, LGG, and PAAD; worse PFI in GBM, LGG, LIHC, and PAAD; worse DSS in ACC, BRCA, GBM, LGG, PAAD, and PRAD; and worse DFI in PAAD.